WuXi makes strategic acquisitions to increase biologics manufacturing

By The Science Advisory Board staff writers

May 7, 2021 -- WuXi Biologics has acquired manufacturing facilities from Bayer in Germany and from Pfizer in China. The company has also acquired CMAB Biopharma, a biologics contract development and manufacturing organization (CDMO) in China.

Under an agreement with Bayer, WuXi has taken over operations and assets of a drug substance facility located in Wuppertal, Germany, which includes three 1,000-L prefusion and six 2,000-L fed-batch bioreactors with independent downstream suites.

In March, WuXi acquired a biologics drug substance and product facility from Pfizer located in Hangzhou, China. This facility includes two 2,000-L single-use bioreactors that can be expanded to four bioreactors. The site also contains two drug product manufacturing facilities for drug product formulation and vial/syringe filling.

Lastly, WuXi acquired CMAB, which has operations in Suzhou, China. CMAB facilities include 7,000-L bioreactor drug substance capacity as well as drug product manufacturing for liquid and lyophilization fills. WuXi Biologics acquired 100% interest of CMAB, which will be renamed as WuXi Biologics (Suzhou) and operate as a wholly owned subsidiary.

With these acquisitions, WuXi Biologics has 11 facilities in China, the U.S., and Germany with a good manufacturing practice (GMP) manufacturing capacity of over 150,000-L. Moreover, the company will now have nine GMP drug product facilities for vials and syringes.

Exelixis licenses antibody panel from WuXi Biologics
Exelixis and WuXi Biologics have entered into an exclusive license agreement to support the expansion of Exelixis' oncology pipeline.
WuXi Biologics opens world's largest biomanufacturing line
WuXi Biologics said that its MFG5 drug-substance manufacturing facility in China has initiated good manufacturing practices-compliant operation on a 36,000-L...
Tubulis, WuXi partner to bring antibody-drug conjugates to clinical trials
Tubulis and WuXi Biologics have announced a strategic collaboration to manufacture Tubulis' next-generation antibody-drug conjugates toward investigational...
ViGeneron partners with WuXi for gene therapy manufacturing
ViGeneron and WuXi Advanced Therapies have announced the formation of a strategic partnership to accelerate the clinical development of VG901, a next-generation...

Copyright © 2021 scienceboard.net

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter